Leveraging the Million Veteran Program Infrastructure and Data for a Rapid Research Response to COVID-19.


Journal

Federal practitioner : for the health care professionals of the VA, DoD, and PHS
ISSN: 1078-4497
Titre abrégé: Fed Pract
Pays: United States
ID NLM: 9500574

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 5 4 2024
Statut: ppublish

Résumé

The Veterans Health Administration Office of Research and Development (ORD) played a key role in the federal government's response to the COVID-19 pandemic. The ORD effectively leveraged existing resources to answer questions related to the SARS-CoV-2 virus and COVID-19. When the COVID-19 pandemic hit in 2020, the Million Veteran Program (MVP), one of the largest genomic cohorts in the world, extended the centralized recruitment and enrollment infrastructure to develop a COVID-19 research volunteer registry to assist enrollment in the vaccine and treatment trials in which the US Department of Veterans Affairs (VA) participated. In addition, the MVP allowed for new data collection and a large genomic cohort to understand host contributions to COVID-19. This article describes ways the MVP contributed to the VA's rapid research response to COVID-19. Several host genetic factors believed to play a role in the development and severity of COVID-19 were identified. Furthermore, existing MVP partnerships with other federal agencies, particularly with the Department of Energy, were leveraged to improve understanding and management of COVID-19. A previously established enterprise approach and research infrastructure were essential to the VA's successful and timely COVID-19 research response. This infrastructure not only supported rapid recruitment in vaccine and treatment trials, but also leveraged the unique MVP and VA electronic health record data to drive rapid scientific discovery and inform clinical operations. Extending the models that VA research applied to the federal government at large and establishing centralized resources for shared or federated data analyses across federal agencies will better equip the nation to respond to future public health crises.

Sections du résumé

Background UNASSIGNED
The Veterans Health Administration Office of Research and Development (ORD) played a key role in the federal government's response to the COVID-19 pandemic. The ORD effectively leveraged existing resources to answer questions related to the SARS-CoV-2 virus and COVID-19.
Observations UNASSIGNED
When the COVID-19 pandemic hit in 2020, the Million Veteran Program (MVP), one of the largest genomic cohorts in the world, extended the centralized recruitment and enrollment infrastructure to develop a COVID-19 research volunteer registry to assist enrollment in the vaccine and treatment trials in which the US Department of Veterans Affairs (VA) participated. In addition, the MVP allowed for new data collection and a large genomic cohort to understand host contributions to COVID-19. This article describes ways the MVP contributed to the VA's rapid research response to COVID-19. Several host genetic factors believed to play a role in the development and severity of COVID-19 were identified. Furthermore, existing MVP partnerships with other federal agencies, particularly with the Department of Energy, were leveraged to improve understanding and management of COVID-19.
Conclusions UNASSIGNED
A previously established enterprise approach and research infrastructure were essential to the VA's successful and timely COVID-19 research response. This infrastructure not only supported rapid recruitment in vaccine and treatment trials, but also leveraged the unique MVP and VA electronic health record data to drive rapid scientific discovery and inform clinical operations. Extending the models that VA research applied to the federal government at large and establishing centralized resources for shared or federated data analyses across federal agencies will better equip the nation to respond to future public health crises.

Identifiants

pubmed: 38577307
doi: 10.12788/fp.0416
pii: fp-40-11s-23
pmc: PMC10988626
doi:

Types de publication

Journal Article

Langues

eng

Pagination

S23-S28

Informations de copyright

Copyright © 2023 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Déclaration de conflit d'intérêts

Author disclosures: The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Auteurs

Stacey B Whitbourne (SB)

Veterans Affairs Boston Healthcare System, Massachusetts.
Brigham and Women's Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Jennifer Moser (J)

Office of Research and Development, Department of Veterans Affairs, Washington, DC.

Kelly Cho (K)

Veterans Affairs Boston Healthcare System, Massachusetts.
Brigham and Women's Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Jennifer Deen (J)

Office of Research and Development, Department of Veterans Affairs, Washington, DC.

Lori L Churby (LL)

Veterans Affairs Palo Alto Healthcare System, California.

Amy C Justice (AC)

Veterans Affairs Connecticut Healthcare System, West Haven.
Yale University School of Medicine and School of Public Health, New Haven, Connecticut.

Juan P Casas (JP)

Novartis Institute for Biomedical Research, Cambridge, Massachusetts.

Saiju Pyarajan (S)

Veterans Affairs Boston Healthcare System, Massachusetts.

Phil S Tsao (PS)

Veterans Affairs Palo Alto Healthcare System, California.
Stanford University School of Medicine, Palo Alto, California.

J Michael Gaziano (JM)

Veterans Affairs Boston Healthcare System, Massachusetts.
Brigham and Women's Hospital, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Sumitra Muralidhar (S)

Office of Research and Development, Department of Veterans Affairs, Washington, DC.

Classifications MeSH